TYME’s Novel Metabolic-Based Cancer Therapy, SM-88, Improves Survival in Phase II Study

Life Science Investing News

Tyme Technologies (NASDAQ:TYME), an emerging biotechnology company developing metabolic-based cancer therapies announces that an open label phase II clinical trial evaluating SM-88 as a monotherapy in end-stage patients with advanced pancreatic cancer demonstrated substantially improved survival benefit compared to expected median overall survival outcomes. As quoted in the press release: “We have no real options …

Tyme Technologies (NASDAQ:TYME), an emerging biotechnology company developing metabolic-based cancer therapies announces that an open label phase II clinical trial evaluating SM-88 as a monotherapy in end-stage patients with advanced pancreatic cancer demonstrated substantially improved survival benefit compared to expected median overall survival outcomes.

As quoted in the press release:

“We have no real options for treating end-of-life patients with advanced pancreatic cancer,” said Dr. Vincent Picozzi, Director of the Pancreaticobiliary Program at the Floyd & Delores Jones Cancer Institute at Virginia Mason Medical Center, Principal Investigator in the Tyme Phase II metastatic pancreatic cancer trial, and a Precision Promise Committee Chair. “The current survival when considering the safety of SM-88, offers new hope to both patients and physicians seeking viable treatment options for advanced patients.”

SM-88 was well tolerated with only 2 (6.5%) serious adverse events (SAEs) deemed at least potentially-related to SM-88.  These SAEs both occurred in one patient, who continued on SM-88 treatment.

The 88-Panc results are from an investigational study. SM-88 is not approved for the treatment of patients with advanced pancreatic cancer.

Click here to read the full press release.

The Conversation (0)
×